Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Arcus Biosciences, Inc. reported revenue of $247M, down 4.3% year over year. Operating margin was -156.3% and net margin -142.9%, on a free-cash-flow margin of -196.0% with capital expenditure at 0.8% of revenue. Every figure is computed directly from RCUS's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $247M | -156.3% | -142.9% |
| FY2024 | $258M | -127.9% | -109.7% |
| FY2023 | $117M | -290.6% | -262.4% |
| FY2022 | $112M | -250.0% | -238.4% |
| FY2021 | $383M | 14.1% | 13.8% |
How does RCUS compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.